Screener
BridgeBio Pharma BBIO Redeemable convertible noncontrolling interests
Redeemable convertible noncontrolling interests at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept bbio:TemporaryEquityCarryingAmountNetIncludingPortionAttributableToNoncontrollingInterests.
The source filing: BridgeBio Pharma’s 10-Q, filed August 10, 2026.
- Filed
- Aug 10, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001743881-26-000027
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Other long-term liabilities | 240 | 244 |
| Total liabilities | 3,723,192 | 3,012,606 |
| Commitments and contingencies (Note 7) | ||
| Redeemable convertible noncontrolling interests | (1,018) | (570) |
| Stockholders’ deficit: | ||
| Undesignated preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued and outstanding | — | — |
| Common stock, $0.001 par value; 500,000,000 shares authorized; 205,867,350 shares issued and 195,284,352 shares outstanding as of June 30, 2026; 202,369,129 shares issued and 194,771,957 shares outstanding as of December 31, 2025 | 206 | 202 |
| Treasury stock, at cost; 10,582,998 shares as of June 30, 2026; 7,597,172 shares as of December 31, 2025 | (533,279) | (323,276) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's redeemable convertible noncontrolling interests?
- BridgeBio Pharma (BBIO) reported redeemable convertible noncontrolling interests of -$1.02M in Q2 2026.
- What does redeemable convertible noncontrolling interests mean?
- Redeemable convertible noncontrolling interests as reported by BridgeBio Pharma, Inc. Common Stock.
Ask your AI about BridgeBio Pharma's redeemable convertible noncontrolling interests.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude